An early lung cancer detection project co-led by the University of Colorado Cancer Center is expanding to two new states.

Novartis has teamed up with Ratio Therapeutics in a $745m licensing and collaboration agreement to advance ...

The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

They need to find a bigger venue,” an attendee mutters as they pull their coat tight and brave the British rain to find one ...

Ideaya Biosciences has made a key hire in anticipation of the launch of its first drug, securing the services of an executive ...

On Tuesday, company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report). The company’s shares closed yesterday at $56.80. Don't ...

every administration, there’s been a health care factor,” David Elkins, the chief financial official of Bristol Myers Squibb, ...

Within 10 years of Crohn's disease diagnosis, up to 50% of people will require surgery, with ileocaecal or ileocolonic resection being the most common procedure.1 Surgery is not curative and disease ...

CHICAGO -- Gene therapy for Danon disease, a rare inherited cause of hypertrophic cardiomyopathy, appeared to improve or ...

Bristol Myers reports promising preliminary results for its next-gen CAR T therapy CC-97540, showing safety and early efficacy in a Phase 1 study for severe autoimmune diseases.